Pages that link to "Q34292940"
Jump to navigation
Jump to search
The following pages link to Bone marrow angiogenesis and progression in multiple myeloma. (Q34292940):
Displaying 50 items.
- MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment (Q26765477) (← links)
- Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies (Q26770838) (← links)
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential (Q28075927) (← links)
- Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma (Q28077635) (← links)
- Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors (Q28487743) (← links)
- Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity (Q31135653) (← links)
- Thalidomide for previously untreated indolent or smoldering multiple myeloma (Q33146651) (← links)
- Endothelial progenitor cells display clonal restriction in multiple myeloma. (Q33247497) (← links)
- Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation (Q33322921) (← links)
- Thalidomide-induced severe neutropenia during treatment of multiple myeloma (Q33361034) (← links)
- Lenalidomide in the treatment of multiple myeloma (Q33376390) (← links)
- Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma (Q33408052) (← links)
- The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies (Q33536301) (← links)
- Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis (Q33748979) (← links)
- HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma (Q33794361) (← links)
- Prognostic factors in multiple myeloma (Q33811615) (← links)
- Advances in the understanding of myeloma bone disease and tumour growth (Q33829022) (← links)
- Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. (Q33829094) (← links)
- Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies (Q33874179) (← links)
- Current status of antiangiogenic factors (Q33962049) (← links)
- The role of the vascular phase in solid tumor growth: a historical review (Q33997842) (← links)
- Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging (Q34069060) (← links)
- Thalidomide in cancer (Q34119619) (← links)
- Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas (Q34140326) (← links)
- Clinical translation of angiogenesis inhibitors (Q34152769) (← links)
- Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis (Q34155848) (← links)
- CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma (Q34209313) (← links)
- Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies (Q34253548) (← links)
- Vascular endothelial growth factor and its receptors in multiple myeloma. (Q34265556) (← links)
- Angiogenesis and leukemia (Q34276799) (← links)
- Immunomodulatory drugs in multiple myeloma (Q34325722) (← links)
- Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma (Q34326518) (← links)
- The role of mast cells in tumour angiogenesis (Q34459084) (← links)
- Chemotherapy and Other Systemic Therapies for Hepatocellular Carcinoma and Liver Metastases (Q34563336) (← links)
- Angiogenesis in hematologic malignancies and its clinical implications (Q34630626) (← links)
- Relapsed multiple myeloma (Q34678309) (← links)
- Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. (Q34683987) (← links)
- Intra-tumoural microvessel density in human solid tumours. (Q34708258) (← links)
- Thalidomide in the treatment of multiple myeloma (Q34734291) (← links)
- Novel therapies for multiple myeloma (Q34774264) (← links)
- Chick embryo chorioallantoic membrane as a useful tool to study angiogenesis (Q34903811) (← links)
- Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders (Q34996327) (← links)
- Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression (Q35089199) (← links)
- The use of novel agents in the treatment of relapsed and refractory multiple myeloma (Q35097319) (← links)
- Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model (Q35103092) (← links)
- Advances in the treatment of multiple myeloma: the role of thalidomide (Q35104386) (← links)
- Management of renal dysfunction in multiple myeloma (Q35116236) (← links)
- Novel Therapies in Multiple Myeloma (Q35121620) (← links)
- Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies (Q35132241) (← links)
- Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3 (Q35166712) (← links)